THIS WEBSITE USES COOKIES
We use cookies to personalise content, to provide social media features, and to analyse our traffic. By choosing 'allow all cookies', you consent to our cookies.
To find out more, read our privacy policy and cookie policy.
DITRAP brings together five organisations with complementary expertise spanning drug development, AI-based patient stratification, clinical validation, health-economic assessment and the integration of project results into clinical practice.
RemAb Therapeutics (RemAb) is the coordinator of DITRAP and is a biopharmaceutical company specialising in the identification, characterisation and selective removal of harmful antibodies through its proprietary Harmful Antibody Removal Technology (HART)
Tampere University (TAU) contributes expertise in artificial intelligence for healthcare, developing decision-support and risk prediction tools to identify ICU patients most likely to benefit from treatment and supporting the evaluation of treatment efficacy.
University Medical Center Groningen (UMCG) provides health technology assessment and health economics capabilities to evaluate the economic impact, cost-effectiveness and potential healthcare value of the DITRAP approach.
ADKNOMA Health Research (ADKNOMA) supports the implementation of DITRAP’s Phase 2 clinical trial through its experience in clinical trial management and monitoring, building on its previous collaboration with RemAb.
European Society of Anaesthesiology and Intensive Care (ESAIC) is a leading European medical society representing anaesthesiology and intensive care professionals. ESAIC leads training activities, including educational resources and engagement with the clinical community.
